Results 61 to 70 of about 3,081 (193)

The impact of Bruton’s tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia

Frontiers in Oncology
BackgroundImpact of B-cell depletion following treatment with Bruton tyrosine kinase-inhibitors (BTKi) on the outcome of SARS-CoV-2 infection in chronic lymphocytic leukemia (CLL) patients remain controversial.
Shenmiao Yang, Rong Wei, Hongxia Shi, Yazhe Wang, Yueyun Lai, Xiaosu Zhao, Jin Lu, Norbert Schmitz, Norbert Schmitz   +8 more
doaj   +1 more source

Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi

Mantle cell lymphoma (MCL) is a rare lymphoproliferative neoplasm considered incurable, with a median survival of 3–5 years. In recent years, Bruton's tyrosine kinase inhibitors (BTKi) have been introduced, demonstrating high therapeutic activity ...
Gaidano G., Clerico M., Fabbri A., Zilioli V. R., Visco C., Re A., Olivieri J., Lucchini E., Zaja F., Dodero A., Tani M., Arcaini L., Castiglione A., Cavallo F.   +13 more
core   +2 more sources

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, Volume 117, Issue 4, Page 750-766, October 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL

Frontiers in Immunology
BackgroundAnti-CD19 chimeric antigen receptor (CAR)-T cell therapy has demonstrated clinical potential in treating relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL); however, enhancing its therapeutic efficacy remains a significant ...
Jia Wang, Rui Cui, Yao Qi, Juan Mu, Xin Li, Qing Li, Qi Deng   +6 more
doaj   +1 more source

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma

International Journal of Cancer, Volume 159, Issue 6, Page 1499-1509, 15 September 2026.
Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang, Jia Li, Luming Cao, Ying Zhang, Xin Wan, Xingtong Wang, Yangzhi Zhao, Zhaoxia Li, Chengqian Chen, Yang Song, Ou Bai   +10 more
wiley   +1 more source

SCOPING OUT CARDIOVASCULAR ASSESSMENT ON INITIATION AND SUBSEQUENT MONITORING DURING BTKI THERAPY, AN ERIC INITIATIVE

Background:BTK inhibitors (BTKi) have revolutionized the treatment landscape of chronic lymphocytic leukemia (CLL),leading to improved outcomes. However, BTKis are also associated with cardiovascular (CV) adverse eventsthat limit their use.Aims:We aimed ...
Miguel Argüello de Tomás, Martin Spacek, Uttam Kumar Nath, Marten Nijziel, Shaimaa El-Ashwah, Arnon P. Kater, Viola Maria Popov, Tamar Tadmor, Fatima Miras Calvo, Peter Turcsanyi, Francesca Maria Quaglia, Agnieszka Szymczyk, Alexandre Sotero Caio, Daniela Georgescu, Micahil Iskas, Farooq Wandroo, Ozren Jaksic, Osman Radhwi, Lucrecia Yanez, Luca Laurenti, Anna Ewa Wolska-Washer, Elżbieta Kalicińska, Leonidas Benetatos, Gilad Itchaki, Gerassimos Pangalis, Gian Matteo Rigolin, Salma Elashwah, Lydia Scarfò, Jorge LABRADOR, Alessandro Sanna, Andrea Visentin, Lucia Farina, Seda Aydin, Matevz Skerget, Yervand Hakobyan, Eleftheria Hatzimichael, Florian Simon, Sotiria Dimou-Besikli, Raul Cordoba, Maria Kislova, Sofia Chatzileontiadou, Regina Pileckyte, Mohamed Yassin, Darko Antic, Celso Arrais-Rodrigues, Ruth Clifford, Maria Dimou, Oana Stanca, Alexander Gatt, Stephen Mulligan, Gloria Ines Iacoboni Garcia-Calvo, Alexa Metaxa, Riccardo Moia, Ewa Wasik-Szczepanek, Yotam Bronstein, Niki Stavrogianni, Sandra Basic Kinda, Christos Varelas, Vasko Graklanov, Münci Yağcı, Michael Doubek, Ángel Ramirez Payer, Augusto Miroli, Mar Bellido, Paolo Sportoletti, Carolyn Owen, Talha Munir, Dominik Chraniuk, Marta Morawska, Shankara Paneesha, Martin Simkovic, Jose Angel Hernandez Rivas, Vladimir Strugov, Candida Vitale, Ernesto Pérez Persona, Paolo Ghia, Julio Marcial Pose Cabarcos, Gioacchino Catania, Alberto Lopez Garcia, Róbert Szász, Zorica Cvetkovic, Jose Antonio Garcia Vela, Thomas Chatzikonstantinou, Nil Albiol, Kostas Stamatopoulos, Mehreen Khan, Alicia Ines Enrico, Anna Gourevitch   +87 more
core   +1 more source

Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real‐World Analysis From REALYSA, a LYSA Cohort

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Although clinical trials showed outcomes improvement in MCL, their applicability to real‐world practice remains limited. Using the prospective REALYSA registry (NCT03869619), we evaluated contemporary management, highlighting evolving practices and differences by age. Among 295 patients, 63% were ≥ 65 years, 48% had a high‐risk MIPI score with
Morgane Cheminant, Patrick Fogarty, Sylvain Carras, Clémentine Sarkozy, Cédric Rossi, Luc Fornecker, Bijou Fontanet, Adrien Chauchet, Sandra Leguyader‐Peyrou, Laure Lebras, Lucie Oberic, Loïc Ysebaert, Ghandi Damaj, Gaelle Labouré, Ludovic Fouillet, Stéphanie Guidez, François Lemonnier, Krimo Bouabdallah, Thomas Gastinne, Nadine Morineau, Sandy Amorim, Fabrice Jardin, Julie Abraham, Roch Houot, Catherine Thieblemont, Franck Morschhauser, Rémy Gressin, Steven Le Gouill, Olivier Hermine, Fanny Cherblanc, Alain Monnereau, Aurélien Belot, Hervé Ghesquieres, Benoit Tessoulin   +33 more
wiley   +1 more source

Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs

Journal of Comparative Effectiveness Research
Aim: Bruton’s tyrosine kinase inhibitors (BTKis), including ibrutinib and acalabrutinib, transformed the treatment landscape of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) by improving outcomes compared with ...
Lindsey Fitzgerald, Sabyasachi Ghosh, Alex Bokun, Angela Lax, Fan Mu, Eric Wu, Yilu Lin, Lizheng Shi, Zaina P Qureshi, Solomon A Graf   +9 more
doaj   +1 more source

Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

British Journal of Haematology, Volume 209, Issue 3, Page 1010-1019, September 2026.
Summary Chronic lymphocytic leukaemia (CLL) primarily affects elderly patients with comorbidities, yet real‐world data on acalabrutinib, a second‐generation Bruton's Tyrosine Kinase (BTK) inhibitor, remain limited outside clinical trials, particularly in Italy.
Andrea Duminuco, Dario Leotta, Alessandro Allegra, Daniele Caracciolo, Laura Caruso, Annalisa Chiarenza, Vittorio Del Fabro, Valentina Di Martina, Amalia Figuera, Paolo Fabio Fiumara, Massimo Gentile, Vanessa Innao, Salvatrice Mancuso, Enrica Antonia Martino, Antonio Mosca, Giovanna Motta, Francesca Pedalino, Marco Rossi, Fabio Stagno, Giorgio Tona, Francesco Di Raimondo, Giuseppe Alberto Palumbo   +21 more
wiley   +1 more source

Clinical outcomes of the chemo‐free approach in relapsed/refractory follicular lymphoma: A network meta‐analysis

British Journal of Haematology, Volume 209, Issue 3, Page 874-886, September 2026.
Graphical overview of the network meta‐analysis (NMA) evaluating chemo‐free approaches for relapsed/refractory follicular lymphoma (R/R FL). Epcoritamab plus rituximab (R2) achieved the highest cumulative ranking probability (SUCRA) across efficacy end‐points but increases the risk of predictable toxicity over anti‐CD20 monotherapy.
Daniele Caracciolo, Maria Rita Lombardo, Gianluca Reitano, Cristina Napoli, Lucia Fiorillo, Chiara Callerame, Mario Garritano, Alessio Bulotta, Maha Munir, Giulia Pensabene, Emiliano Barbieri, Alberto Bavieri, Pierfrancesco Tassone, Pierosandro Tagliaferri, Stefano Luminari   +14 more
wiley   +1 more source